Life Sciences


Adare Pharma Solutions, a global technology-driven CDMO specializing in oral dosage forms, today announced expansions of its high potency handling capabilities in the United States and Europe.


In the United States, a second high potency suite is being added to Adare’s 128,000 sq ft (12,000 sq m) Orthodox Street facility in Philadelphia. The suite will provide encapsulation, high-shear granulation, blending, and other manufacturing processes. Construction of the new suite will be completed by Q4 of 2024 and will complement the site’s existing potent suite, which provides roller compaction, milling, bin blending, and tablet compression.

The Orthodox Street site will also add a bottle packaging line providing turnkey support for highly potent clinical supplies and commercial products. The high potency bottle packaging line will be operational in Q4 of 2024.

The 179,000 sq ft (16,600 sq m) Vandalia facility in Ohio will upgrade several R&D-to-clinical stage production suites to provide high potency handling. Capabilities will include dry roller compaction, microencapsulation, and fluid bed processing. Work is already underway at the site and is scheduled for completion by Q4 of 2024.

“We have seen demand for high potency handling and packaging continue to increase, with around half of solid dose drugs in development being highly potent,” commented Tom Sellig, CEO of Adare Pharma Solutions. “This proactive investment across our global network of sites will ensure we continue to provide customers with the oral dose capabilities and capacity they will need both now and in the future.”

In Europe, Adare’s 220,000 sq ft (20,400 sq m) Pessano facility in Milan, Italy will add high potency upgrades to its analytical and formulation laboratories, including fluid bed processing, bin blending, compression, encapsulation, and pan-coating capabilities.

The Pessano site also recently announced plans to add packaging capabilities and more warehousing capacity, as well as high-shear granulation mixing that can utilize either aqueous or organic-based solutions. These expansions, as well as the high potency upgrades, will be operational by the end of 2024.